JP2005518368A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005518368A5 JP2005518368A5 JP2003549317A JP2003549317A JP2005518368A5 JP 2005518368 A5 JP2005518368 A5 JP 2005518368A5 JP 2003549317 A JP2003549317 A JP 2003549317A JP 2003549317 A JP2003549317 A JP 2003549317A JP 2005518368 A5 JP2005518368 A5 JP 2005518368A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- formula
- compound
- halogen
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 30
- 229910052736 halogen Inorganic materials 0.000 claims 23
- 150000002367 halogens Chemical class 0.000 claims 23
- 125000003118 aryl group Chemical group 0.000 claims 15
- 125000001072 heteroaryl group Chemical group 0.000 claims 15
- 125000000623 heterocyclic group Chemical group 0.000 claims 15
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 6
- 125000004845 (C1-C6) alkylsulfonylamino group Chemical group 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 4
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 4
- 125000004750 (C1-C6) alkylaminosulfonyl group Chemical group 0.000 claims 4
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 4
- 239000004202 carbamide Substances 0.000 claims 4
- -1 cyano, amino Chemical group 0.000 claims 4
- 206010020853 Hypertonic bladder Diseases 0.000 claims 3
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000027939 micturition Effects 0.000 claims 2
- 239000003149 muscarinic antagonist Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000000241 respiratory effect Effects 0.000 claims 2
- NKHBRICCVXXZEY-UHFFFAOYSA-N 1-[4-[(7-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)-propylamino]piperidin-1-yl]ethanone Chemical compound C1CC2=CC=C(OC)C=C2CC1N(CCC)C1CCN(C(C)=O)CC1 NKHBRICCVXXZEY-UHFFFAOYSA-N 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010021639 Incontinence Diseases 0.000 claims 1
- 208000008238 Muscle Spasticity Diseases 0.000 claims 1
- 208000029578 Muscle disease Diseases 0.000 claims 1
- 208000021642 Muscular disease Diseases 0.000 claims 1
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims 1
- QAHIMRFXRHCIOG-UHFFFAOYSA-N [4-[(6,7-dimethoxy-1,2,3,4-tetrahydronaphthalen-2-yl)-propylamino]piperidin-1-yl]-piperazin-1-ylmethanone Chemical compound C1CC2=CC(OC)=C(OC)C=C2CC1N(CCC)C(CC1)CCN1C(=O)N1CCNCC1 QAHIMRFXRHCIOG-UHFFFAOYSA-N 0.000 claims 1
- DQKILXZDCFYBEZ-UHFFFAOYSA-N [4-[(6,7-dimethoxy-1,2,3,4-tetrahydronaphthalen-2-yl)-propylamino]piperidin-1-yl]-piperidin-4-ylmethanone Chemical compound C1CC2=CC(OC)=C(OC)C=C2CC1N(CCC)C(CC1)CCN1C(=O)C1CCNCC1 DQKILXZDCFYBEZ-UHFFFAOYSA-N 0.000 claims 1
- VXFXLZREKZSIKG-UHFFFAOYSA-N [4-[(7-bromo-1,2,3,4-tetrahydronaphthalen-2-yl)-propylamino]piperidin-1-yl]-piperidin-4-ylmethanone Chemical compound C1CC2=CC=C(Br)C=C2CC1N(CCC)C(CC1)CCN1C(=O)C1CCNCC1 VXFXLZREKZSIKG-UHFFFAOYSA-N 0.000 claims 1
- FEDSKDMGCCFDLP-UHFFFAOYSA-N [4-[(7-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)-propylamino]piperidin-1-yl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CC2=CC=C(OC)C=C2CC1N(CCC)C(CC1)CCN1C(=O)N1CCN(C)CC1 FEDSKDMGCCFDLP-UHFFFAOYSA-N 0.000 claims 1
- UVJLNVPSONWHRV-UHFFFAOYSA-N [4-[(7-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)-propylamino]piperidin-1-yl]-morpholin-4-ylmethanone Chemical compound C1CC2=CC=C(OC)C=C2CC1N(CCC)C(CC1)CCN1C(=O)N1CCOCC1 UVJLNVPSONWHRV-UHFFFAOYSA-N 0.000 claims 1
- WAVWSOSLFSWYEM-UHFFFAOYSA-N [4-[(7-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)-propylamino]piperidin-1-yl]-piperazin-1-ylmethanone Chemical compound C1CC2=CC=C(OC)C=C2CC1N(CCC)C(CC1)CCN1C(=O)N1CCNCC1 WAVWSOSLFSWYEM-UHFFFAOYSA-N 0.000 claims 1
- KTAULCNFQYFKTN-HSZRJFAPSA-N [4-[[(2r)-7-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl]-propylamino]piperidin-1-yl]-piperidin-4-ylmethanone Chemical compound CCCN([C@H]1CC2=CC(OC)=CC=C2CC1)C(CC1)CCN1C(=O)C1CCNCC1 KTAULCNFQYFKTN-HSZRJFAPSA-N 0.000 claims 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 1
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000008602 contraction Effects 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 125000005959 diazepanyl group Chemical group 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 claims 1
- 208000020629 overactive bladder Diseases 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 210000002460 smooth muscle Anatomy 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 208000018198 spasticity Diseases 0.000 claims 1
- 210000005070 sphincter Anatomy 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33667501P | 2001-12-03 | 2001-12-03 | |
| PCT/EP2002/013219 WO2003048125A1 (en) | 2001-12-03 | 2002-11-25 | Aminotetralin derivatives as muscarinic receptor antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005518368A JP2005518368A (ja) | 2005-06-23 |
| JP2005518368A5 true JP2005518368A5 (enExample) | 2005-12-22 |
| JP4322675B2 JP4322675B2 (ja) | 2009-09-02 |
Family
ID=23317154
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003549317A Expired - Fee Related JP4322675B2 (ja) | 2001-12-03 | 2002-11-25 | ムスカリン受容体アンタゴニストとしてのアミノテトラリン誘導体 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US6635658B2 (enExample) |
| EP (1) | EP1453806B1 (enExample) |
| JP (1) | JP4322675B2 (enExample) |
| KR (1) | KR100668231B1 (enExample) |
| CN (1) | CN100358870C (enExample) |
| AR (1) | AR037611A1 (enExample) |
| AT (1) | ATE381541T1 (enExample) |
| AU (1) | AU2002352124A1 (enExample) |
| BR (1) | BR0214649A (enExample) |
| CA (1) | CA2469055C (enExample) |
| DE (1) | DE60224221T2 (enExample) |
| ES (1) | ES2297029T3 (enExample) |
| MX (1) | MXPA04005313A (enExample) |
| PL (1) | PL370799A1 (enExample) |
| RU (1) | RU2311408C2 (enExample) |
| WO (1) | WO2003048125A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL370799A1 (en) * | 2001-12-03 | 2005-05-30 | F.Hoffmann-La Roche Ag | Aminotetralin derivatives as muscarinic receptor antagonists |
| EA200500173A1 (ru) | 2002-07-08 | 2005-08-25 | Рэнбакси Лабораториз Лимитед | Производные 3,6-дизамещенного азабицикло[3.1.0]гексана в качестве антагонистов мускариновых рецепторов |
| US7488748B2 (en) * | 2003-01-28 | 2009-02-10 | Ranbaxy Laboratories Limited | 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists |
| EP1618091A1 (en) | 2003-04-09 | 2006-01-25 | Ranbaxy Laboratories, Ltd. | Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists |
| WO2004089900A1 (en) | 2003-04-11 | 2004-10-21 | Ranbaxy Laboratories Limited | Azabicyclo derivatives as muscarinic receptor antagonists |
| EP1781300A1 (en) | 2004-07-16 | 2007-05-09 | ProteoSys AG | Muscarinic antagonists with parp and sir modulatng activity as agents for inflammatory diseases |
| WO2006035303A1 (en) * | 2004-09-29 | 2006-04-06 | Ranbaxy Laboratories Limited | Muscarinic receptor antagonists |
| WO2006054162A1 (en) * | 2004-11-19 | 2006-05-26 | Ranbaxy Laboratories Limited | Azabicyclic muscarinic receptor antagonists |
| EP1828126A1 (en) * | 2004-12-15 | 2007-09-05 | Ranbaxy Laboratories Limited | Acid addition salts of muscarinic receptor antagonists |
| US9198897B2 (en) * | 2005-01-19 | 2015-12-01 | Neurohealing Pharmaceuticals, Inc. | Methods and compositions for decreasing saliva production |
| MX2007011453A (es) * | 2005-04-22 | 2008-02-12 | Alantos Pharmaceuticals Holding Inc | Inhibidores de la dipeptidil peptidasa-iv. |
| US20080319043A1 (en) * | 2005-05-03 | 2008-12-25 | Mohammad Salman | 3,6-Disubstituted Azabicyclo (3.1.0) Hexane Derivatives as Muscarinic Receptor Antagonists |
| EP2387405A2 (en) | 2009-01-13 | 2011-11-23 | ProteoSys AG | Pirenzepine as an agent in cancer treatment |
| NZ716598A (en) * | 2012-11-20 | 2017-02-24 | Merial Inc | Anthelmintic compounds and compositions and method of using thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3718317A1 (de) * | 1986-12-10 | 1988-06-16 | Bayer Ag | Substituierte basische 2-aminotetraline |
| CA1331191C (en) | 1988-03-25 | 1994-08-02 | Bengt Ronny Andersson | Therapeutically useful tetralin derivatives |
| FR2659323B1 (fr) | 1990-03-07 | 1992-06-12 | Synthelabo | Derives de 4-(aminomethyl) piperidine, leur preparation et leur application en therapeutique. |
| FR2659853A1 (fr) | 1990-03-22 | 1991-09-27 | Midy Spa | Utilisation de derives 2-aminotetraliniques pour la preparation de medicaments destines a combattre les troubles de la motricite intestinale. |
| MY110227A (en) * | 1991-08-12 | 1998-03-31 | Ciba Geigy Ag | 1-acylpiperindine compounds. |
| AU717431B2 (en) * | 1996-07-01 | 2000-03-23 | Schering Corporation | Muscarinic antagonists |
| ATE227708T1 (de) * | 1996-07-10 | 2002-11-15 | Schering Corp | 1,4-disubstituierte piperdine als muskarin- antagonisten |
| US6319920B1 (en) * | 1998-02-27 | 2001-11-20 | Syntex (U.S.A.) Llc | 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives |
| CN1187342C (zh) | 2000-05-25 | 2005-02-02 | 弗·哈夫曼-拉罗切有限公司 | 取代的1－氨基烷基内酰胺化合物及其作为毒蕈碱受体拮抗剂的用途 |
| DE60114413T2 (de) | 2000-05-25 | 2006-07-27 | F. Hoffmann-La Roche Ag | Substituierte 1-aminoalkyl-lactame und deren verwendung als muscarinrezeptor-antagonisten |
| PL370799A1 (en) * | 2001-12-03 | 2005-05-30 | F.Hoffmann-La Roche Ag | Aminotetralin derivatives as muscarinic receptor antagonists |
-
2002
- 2002-11-25 PL PL02370799A patent/PL370799A1/xx not_active Application Discontinuation
- 2002-11-25 MX MXPA04005313A patent/MXPA04005313A/es active IP Right Grant
- 2002-11-25 AT AT02787797T patent/ATE381541T1/de not_active IP Right Cessation
- 2002-11-25 BR BR0214649-5A patent/BR0214649A/pt not_active IP Right Cessation
- 2002-11-25 EP EP02787797A patent/EP1453806B1/en not_active Expired - Lifetime
- 2002-11-25 DE DE60224221T patent/DE60224221T2/de not_active Expired - Lifetime
- 2002-11-25 AU AU2002352124A patent/AU2002352124A1/en not_active Abandoned
- 2002-11-25 JP JP2003549317A patent/JP4322675B2/ja not_active Expired - Fee Related
- 2002-11-25 WO PCT/EP2002/013219 patent/WO2003048125A1/en not_active Ceased
- 2002-11-25 ES ES02787797T patent/ES2297029T3/es not_active Expired - Lifetime
- 2002-11-25 KR KR1020047008423A patent/KR100668231B1/ko not_active Expired - Fee Related
- 2002-11-25 CA CA2469055A patent/CA2469055C/en not_active Expired - Fee Related
- 2002-11-25 CN CNB028240170A patent/CN100358870C/zh not_active Expired - Fee Related
- 2002-11-25 RU RU2004120558/04A patent/RU2311408C2/ru not_active IP Right Cessation
- 2002-12-02 US US10/308,092 patent/US6635658B2/en not_active Expired - Fee Related
- 2002-12-02 AR ARP020104638A patent/AR037611A1/es not_active Application Discontinuation
-
2003
- 2003-06-27 US US10/608,604 patent/US6806278B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007505091A5 (enExample) | ||
| JP2017528507A5 (enExample) | ||
| JP2016512531A5 (enExample) | ||
| JP2006526590A5 (enExample) | ||
| JP2005516067A5 (enExample) | ||
| JP2020523388A5 (enExample) | ||
| JP2010509356A5 (enExample) | ||
| JP2006523216A5 (enExample) | ||
| JP2006182786A5 (enExample) | ||
| JP2004526788A5 (enExample) | ||
| CA2469055A1 (en) | Aminotetralin derivatives as muscarinic receptor antagonists | |
| JP2017528503A5 (enExample) | ||
| JP2017527578A5 (enExample) | ||
| JP2005526723A5 (enExample) | ||
| JP2005519908A5 (enExample) | ||
| JP2005525323A5 (enExample) | ||
| JP2005525322A5 (enExample) | ||
| CN110267945A (zh) | 氰基取代的吲哚化合物及其作为lsd1抑制剂的用途 | |
| JP2009506014A5 (enExample) | ||
| JP2004507527A5 (enExample) | ||
| JP2007522162A5 (enExample) | ||
| EP3661510A1 (en) | Methods of treating behavior alterations | |
| JP2009501745A5 (enExample) | ||
| JP2007538031A5 (enExample) | ||
| JP2005500370A5 (enExample) |